Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) EPS (Weighted Average and Diluted) (2020 - 2025)

Revolution Medicines (RVMD) has 6 years of EPS (Weighted Average and Diluted) data on record, last reported at -$1.89 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 67.26% year-over-year to -$1.89; the TTM value through Dec 2025 reached -$5.95, down 66.2%, while the annual FY2025 figure was -$5.95, 66.2% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$1.89 in Q4 2025 per RVMD's latest filing, down from -$1.62 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.6 in Q2 2021 and bottomed at -$1.89 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.97, with a median of -$0.87 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 101.64% in 2023, then grew 23.91% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.72 in 2021, then grew by 15.69% to -$0.61 in 2022, then tumbled by 101.64% to -$1.23 in 2023, then grew by 8.13% to -$1.13 in 2024, then plummeted by 67.26% to -$1.89 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$1.89 in Q4 2025, -$1.62 in Q3 2025, and -$1.31 in Q2 2025.